TRVI
$0.90
Trevi Therapeutics
($.05)
(5.45%)
TRVI
Earnings Whisper ®
N/A
4th Quarter December 2021
Consensus:  ($0.34)
Revenue:  $0.00 Mil
Wednesday
Feb 9
4:05 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when TRVI reports earnings?
Beat
Meet
Miss

Where is TRVI's stock price going from here?
Up
Flat
Down
Stock chart of TRVI
Analysts
Summary of analysts' recommendations for TRVI
Score
Grade
Pivots
Resistance
$1.07
$1.03
$0.97

$0.92

Support
$0.86
$0.81
$0.75
Tweet
Growth
Description
Trevi Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. The company is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis and levodopa-induced dyskinesia in patients with Parkinson's disease. Trevi Therapeutics Inc. is based in New Haven, Connecticut.